可手术原发HER2阳性乳腺癌早期中期PET的SUV与无复发生存及总生存的相关性(TBCRC026试验)
TBCRC026试验纳入88例II/III期ER阴性、HER2阳性乳腺癌患者,接受新辅助曲妥珠单抗联合帕妥珠单抗(HP)治疗,于基线和C1D15行18F-FDG PET/CT。中位随访53.7个月,C1D15 SULmax≤3与OS改善相关(HR 0.14,95%CI 0.01-0.85,P=0.03),与RFS的关联未达统计学显著(HR 0.36,95%CI 0.11-1.05,P=0.06)。
要点
- C1D15 SULmax≤3与OS改善显著相关(HR 0.14,95%CI 0.01-0.85,P=0.03)。
- C1D15 SULmax≤3与RFS的关联未达统计学显著(HR 0.36,95%CI 0.11-1.05,P=0.06)。
- SULmax较基线下降≥40%与RFS和OS的关联均未达统计学显著。
核心结论
- 首次报告18F-FDG PET/CT C1D15 SULmax≤3与接受单纯新辅助HP治疗的ER阴性、HER2阳性乳腺癌患者的RFS和OS结局存在潜在关联。
- 若在未来研究中得到证实,这一基于影像的生物标志物可能有助于早期个体化治疗。
研究设计与样本
- TBCRC026试验中88例II/III期ER阴性、HER2阳性乳腺癌患者接受新辅助HP治疗。
- 于基线和第1周期第15天(C1D15)行18F-FDG PET/CT,评估SULmax参数与RFS、OS的关系。
主要发现
- 中位随访53.7个月(83/88可评估),6例死亡,14例RFS事件。
- 3年RFS估计值为84%(95%CI 76%-92%),3年OS估计值为92%(95%CI 87%-98%)。
- C1D15 SULmax≤3与RFS改善相关(HR 0.36,95%CI 0.11-1.05,P=0.06),未达统计学显著。
- C1D15 SULmax≤3与OS改善相关(HR 0.14,95%CI 0.01-0.85,P=0.03),达统计学显著。
- SULmax较基线下降≥40%(59%患者达到)与RFS和OS的关联未达统计学显著。
关键数值与推荐
- SULmax较基线下降≥40%或C1D15 SULmax≤3作为18F-FDG PET/CT参数与pCR的关联采用Cox回归评估。
- 单纯HP治疗后pCR率为22%(18/83),28%(25/88)接受额外非研究新辅助治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 事件数较少,采用似然比置信区间报告。
- 原文结论指出若在未来研究中得到证实,该影像生物标志物可能有助于早期个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Predictive biomarkers of response to human epidermal growth factor receptor 2 (HER2)-directed therapy are essential to inform treatment decisions. The TBCRC026 trial reported that early declines in tumor SUVs corrected for lean body mass (SULmax) on 18F-FDG PET/CT predicted a pathologic complete response (pCR) to HER2 therapy with neoadjuvant trastuzumab and pertuzumab (HP) without chemotherapy in estrogen receptor (ER)-negative, HER2-positive breast cancer. We hypothesized that 18F-FDG PET/CT SULmax parameters would predict recurrence-free survival (RFS) and overall survival (OS). Methods: Patients with stage II/III ER-negative, HER2-positive breast cancer received neoadjuvant HP (n = 88). pCR after HP alone was 22% (18/83), additional nonstudy neoadjuvant therapy was administered in 28% (25/88), and the majority received adjuvant therapy per physician discretion. 18F-FDG PET/CT was performed at baseline and at cycle 1, day 15 (C1D15). RFS and OS were summarized using the Kaplan-Meier method and compared between subgroups using logrank tests. Associations between 18F-FDG PET/CT (≥40% decline in SULmax between baseline and C1D15, or C1D15 SULmax ≤ 3) and pCR were evaluated using Cox regressions, where likelihood ratio CIs were reported because of the small numbers of events. Results: Median follow-up was 53.7 mo (83/88 evaluable), with 6 deaths and 14 RFS events. Estimated RFS and OS at 3 y was 84% (95% CI, 76%-92%) and 92% (95% CI, 87%-98%), respectively. A C1D15 SULmax of 3 or less was associated with improved RFS (hazard ratio [HR], 0.36; 95% CI, 0.11-1.05; P = 0.06) and OS (HR, 0.14; 95% CI, 0.01-0.85; P = 0.03), the latter statistically significant. The association of an SULmax decline of at least 40% (achieved in 59%) with RFS and OS did not reach statistical significance. pCR was associated with improved RFS (HR, 0.25; 95% CI, 0.01-1.24; P = 0.10) but did not reach statistical significance. Conclusion: For the first time, we report a potential association between a C1D15 SULmax of 3 or less on 18F-FDG PET/CT and RFS and OS outcomes in patients with ER-negative, HER2-positive breast cancer receiving neoadjuvant HP alone. If confirmed in future studies, this imaging-based biomarker may facilitate early individualization of therapy.
引用
- Hennessy MA, Leal JP, Huang CY, et al. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). J Nucl Med. 2023. PMID: 37652539. doi:10.2967/jnumed.123.265853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。